Compare Abbott Laboratories (ABT) vs UiPath Inc (PATH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs UiPath Inc — how do they compare? Abbott Laboratories trades at $95.83 (market cap $166.94B), while UiPath Inc trades at $11.43 (market cap $6.04B). The key difference: Abbott Laboratories is far larger — about 27.6× UiPath Inc's market cap, and Abbott Laboratories pays a 2.63% dividend while UiPath Inc pays none. Which is the better fit depends on your goals.
| ABT | PATH | |
|---|---|---|
Market Cap | $166.94B | $6.04B |
Sector | Health | Technology |
52-Week High | $136.62 | $19.29 |
52-Week Low | $82.57 | $9.38 |
Enterprise Value | $193.69B | $4.81B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
UiPath (PATH) trades at $11.65, down 0.51% on the day, with a bullish technical signal driven by moving averages. The company shows improving fundamentals with revenue growth from $1.43B in 2025 to a projected $1.7B in 2026 and a shift to profitability. Recent news highlights expansion in agentic AI and enterprise automation, though the stock faces competitive and execution risks.
The outlook is cautiously optimistic with a consensus price target of $13.33 suggesting 14% upside. Key opportunities include strong revenue growth and margin expansion, while risks involve intense competition and the need to sustain AI-driven adoption. Analyst sentiment is mixed with 25% buy ratings amid ongoing transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →
